Highlights in GU cancer at ESMO 2023

The European Society for Medical Oncology (ESMO) Congress 2023, which took place in Madrid, Spain, gathered internationally acclaimed experts to share and deliberate on the most recent breakthroughs in oncology. In this podcast, we listen to prominent healthcare professionals offering a summary of key moments from this year’s conference. We will be joined by Joaquim Bellmunt (Harvard Medical School, Boston, MA), Laurence Albiges (Gustave Roussy Institute, Villejuif, France), Arlene Siefker-Radtke (The MD Anderson Cancer Center, Houston, TX), and Bradley McGregor (Dana Farber Cancer Institute, Boston).

We will hear on updates on pivotal trials including the Phase III EV-302 trial of enfortumab vedotin and pembrolizumab in untreated advanced/metastatic urothelial cancer, as well as the Phase III LITESPARK-005 trial of belzutifan versus everolimus in patients with pretreated advanced clear cell renal cell carcinoma (ccRCC). Additional trials under discussion include the THOR study of erdafitinib versus pembrolizumab in pre-treated patients with urothelial cancer and the DAD trial of sacitizumab govetican and enfortumab vedotin as a second-line therapy in patients with metastatic urothelial carcinoma.

The post Highlights in GU cancer at ESMO 2023 appeared first on VJOncology.